Table 7.
Comparison between patients who developed pazopanib-related cardiovascular toxicity after excluding hypertension
| Patient Characteristics | Pazopanib-induced non-HTN CV toxicity (N = 12) | No Pazopanib-induced non-HTN CV toxicity (N = 23) | P Value |
|---|---|---|---|
| Male Gender | 5 (42) | 15 (65) | 0.282 |
| Age, years | 66 [61–71] | 57 [52–65] | 0.006 |
| LVEF, % | *60 [59–67] | **62.5 [59–66] | 0.712 |
| Systolic BP, mm Hg | 124.1 [120.8–130.8] | 127.7 [122–132.6] | 0.728 |
| Diastolic BP, mm Hg | 70.0 [65.9–73.5] | 72 [67.9–79.3] | 0.297 |
| Heart Failure | 0 (0) | 2 (9) | 0.536 |
| LV Dysfunction | 4 (33) | 3 (13) | 0.200 |
| Diabetes Mellitus | 5 (42) | 10 (43) | 1 |
| Hypertension | 7 (58) | 14 (61) | 1 |
| Dyslipidemia | 8 (67) | 9 (39) | 0.164 |
| GFR < 60 mL/min/1.73 m2 | 9 (75) | 11 (48) | 0.163 |
| CAD/PAD | 3 (25) | 2 (9) | 0.313 |
| CVA/TIA | 3 (25) | 0 (0) | 0.034 |
| Dysrhythmia | 3 (25) | 4 (17) | 0.670 |
| Thromboembolism | 1 (8) | 6 (26) | 0.380 |
| Smoker*, n (%) | 7 (58) | 13 (57) | 1 |
| BMI (kg/m2) | 27.6 [23.6–31.8] | 28.5 [21.9–32.9] | 0.627 |
| ACEIs or ARBs | 6 (50) | 8 (35) | 0.383 |
| Beta Blockers | 4 (33) | 8 (35) | 1 |
| Statin | 6 (50) | 7 (30) | 0.256 |
| Pazopanib dose reduction | 3 (25) | 3 (13) | 0.391 |
| Follow-up time, months | 11.7 [4.2–20.9] | 6.9 [2.1–17.7] | 0.509 |
ACEI angiotensin converting enzyme, ARB angiotensin receptor blocker, BP blood pressure, BMI body mass index, CAD/PAD coronary artery disease/peripheral arterial disease, CCBs calcium channel blockers, ECOG Eastern Cooperative Oncology Group performance status, LVEF left ventricular ejection fraction, GRF glomerular filtration rate; Data presented as a percent (%) or median [1st quartile-3rd quartile]
*
N = 9;
**
N = 16
a
Current or prior smoking history